| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A single administration of hIL-7-hyFc induces long-lasting T-cell expansion with maintained effector functions
|
Kim, Sojeong
|
|
|
6 |
23 |
p. 6093-6107
|
article
|
| 2 |
A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma
|
Thieblemont, Catherine
|
|
|
6 |
23 |
p. 5995-6004
|
article
|
| 3 |
Ayuk FA, Berger C, Badbaran A, et al. Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting. Blood Adv. 2021;5(11):2523-2527.
|
|
|
|
6 |
23 |
p. 6075
|
article
|
| 4 |
C5 inhibition allows continued antineoplastic therapy in cancer- and chemotherapy-associated thrombotic microangiopathy
|
Shah, Hridaya
|
|
|
6 |
23 |
p. 6071-6074
|
article
|
| 5 |
D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study
|
Palareti, Gualtiero
|
|
|
6 |
23 |
p. 6005-6015
|
article
|
| 6 |
Editorial Board
|
|
|
|
6 |
23 |
p. i
|
article
|
| 7 |
Front Matter
|
|
|
|
6 |
23 |
p. ii
|
article
|
| 8 |
GATA1 controls numbers of hematopoietic progenitors and their response to autoimmune neuroinflammation
|
Hwang, Daniel
|
|
|
6 |
23 |
p. 5980-5994
|
article
|
| 9 |
Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL
|
Abramson, Jeremy S.
|
|
|
6 |
23 |
p. 5969-5979
|
article
|
| 10 |
Hematopoietic stem cell transplant for Hurler syndrome: does using bone marrow or umbilical cord blood make a difference?
|
Orchard, Paul J.
|
|
|
6 |
23 |
p. 6023-6027
|
article
|
| 11 |
Identification and characterization of RBM12 as a novel regulator of fetal hemoglobin expression
|
Wakabayashi, Aoi
|
|
|
6 |
23 |
p. 5956-5968
|
article
|
| 12 |
Is donor-recipient sex associated with transfusion-related outcomes in critically ill patients?
|
Wood, Henry
|
|
|
6 |
23 |
p. 6076-6077
|
article
|
| 13 |
Narkhede M, Goyal G, Shea L, et al. Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma. Blood Adv. 2022; 6(14):4122-4131.
|
|
|
|
6 |
23 |
p. 6039
|
article
|
| 14 |
Production and nonclinical evaluation of an autologous iPSC–derived platelet product for the iPLAT1 clinical trial
|
Sugimoto, Naoshi
|
|
|
6 |
23 |
p. 6056-6069
|
article
|
| 15 |
PUM1 mediates the posttranscriptional regulation of human fetal hemoglobin
|
Elagooz, Reem
|
|
|
6 |
23 |
p. 6016-6022
|
article
|
| 16 |
Recurrent switch 2 domain RAC2 mutations in intravascular large B-cell lymphoma
|
Kodgule, Rohan
|
|
|
6 |
23 |
p. 6051-6055
|
article
|
| 17 |
RUNX1 deficiency cooperates with SRSF2 mutation to induce multilineage hematopoietic defects characteristic of MDS
|
Huang, Yi-Jou
|
|
|
6 |
23 |
p. 6078-6092
|
article
|
| 18 |
Temporal in vivo platelet labeling in mice reveals age-dependent receptor expression and conservation of specific mRNAs
|
Armstrong, Paul C.
|
|
|
6 |
23 |
p. 6028-6038
|
article
|
| 19 |
The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes
|
Faruqi, Aiman J.
|
|
|
6 |
23 |
p. 6040-6050
|
article
|
| 20 |
Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19
|
Ripoll, Juan G.
|
|
|
6 |
23 |
p. 5951-5955
|
article
|
| 21 |
Yes, donor-recipient sex is associated with transfusion-related outcomes in critically ill patients
|
Alshalani, Abdulrahman
|
|
|
6 |
23 |
p. 6070
|
article
|
Journal description